Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for Cat Dander-Induced Asthma
NCT00495612Phase 4Completed
- Sponsor
- Genentech
- Start
- Sep 2007
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised, double-blind trial in asthma comparing Omalizumab with Placebo (2 arms). Primary endpoint: Area Under the Curve (AUC) of Percent Change in Forced Expiratory Volume in 1 Second (FEV1) at Week 16. Started Sep 2007; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00495612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00495612.